Corcept says Phase 2 ALS study shows 87% lower death risk with dazucorilant

• Corcept released two-year survival follow-up from Phase 2 DAZALS trial of dazucorilant in amyotrophic lateral sclerosis.
• Exploratory analyses indicated patients initially treated with higher-dose dazucorilant lived longer than patients on placebo who did not switch to the drug in extension follow-up.
• Trial missed its primary endpoint on functional decline, raising execution risk despite favorable survival signal.
• Corcept expects to start a pivotal Phase 3 study later this year as it discusses next steps with regulators.
• Program update included continued acceptable safety profile, with gastrointestinal discomfort cited as most common side effect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202604301605BIZWIRE_USPR_____20260430_BW885863) on April 30, 2026, and is solely responsible for the information contained therein.